Accelerator Life Science Partners

ALSP originates its own companies rather than reviewing external pitch decks. The firm scouts academic research — typically from post-docs and principal investigators at major research universities — identifies commercially viable science, and then stands up a startup around it. This company-creation model means ALSP controls the founding cap table, recruits the CEO, and typically leads the Series A before the company formally exists. The approach allows ALSP to set both the scientific direction and the governance structure from day zero.

Senior Managing Directors Thong Le, Kendall Mohler, and Alex Tkachenko jointly govern investment decisions. Each holds an advanced degree in a life science or physical science discipline, and the firm's investment committee operates on scientific consensus rather than a pure financial-return analysis. Portfolio company formation requires unanimous agreement on the underlying science's therapeutic or diagnostic potential before capital is deployed.

ALSP is a venture studio, not a passive fund. It identifies academic science, writes the business plan, recruits a CEO, provides shared operational infrastructure — lab space, legal, HR — and syndicates the Series A internally. A conventional VC writes a check and monitors quarterly; ALSP acts as a co-founder. This makes the firm structurally closer to Flagship Pioneering or Third Rock Ventures in operating model, though executed at smaller scale and across a network of academic hubs rather than a single campus.

ALSP's primary commitment is at formation and Series A, where it syndicates the founding round with a network of co-investors. The firm maintains reserves for selective follow-on participation in later rounds, but its core model is not to lead Series B or growth equity — those are typically opened to third-party syndicates once the portfolio company has generated proof-of-concept data.

The firm operates incubation hubs in Seattle, New York, and Shanghai, with portfolio support offices in Pasadena, New Brunswick, Chicago, and Research Triangle Park. Portfolio company formation clusters near major academic medical centers — University of Washington, Columbia, NYU, UC system campuses, and Shanghai Jiao Tong University — reflecting ALSP's thesis that scientific talent density predicts startup success better than coastal venture ecosystem proximity.

ALSP targets company formation and Series A stages, with check sizes calibrated to fund drug discovery platforms through preclinical proof-of-concept. Rather than a fixed ticket, the firm commits both operational resources (lab space, back-office support) and capital, aiming to get each portfolio company to a value-inflection point — typically IND filing or Phase 1 data — where a traditional venture syndicate would lead the Series B.

Public records do not indicate a separate philanthropic foundation. ALSP operates as a for-profit venture studio. However, several of the academic institutions ALSP partners with receive NIH and foundation grant funding, and the firm's company-creation model sometimes involves licensing university intellectual property under royalty arrangements that provide economic return to the academic institution.